CT-342 Prolonged Hematologic Toxicity after B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Treatment: from Clinical Data to Ex-Vivo Studies at a Single Center

S526lymphocytes, T-cells carrying T-cell receptors, and T-cells carrying chimeric antigen receptors.During treatment with CAR-T cells, the patient's T lymphocytes were harvested, modified in vitro, and reinfused into the patient to provide greater efficiency and potency in targeting tumor cells.CAR-T immunotherapy has shown remarkable results and has become a promising therapy for treating refractory or relapsed solid cancers.However, several hurdles, such as T cell exhaustion, antigen escape, toxicity, CAR-T cell trafficking, immunosuppressive microenvironment cytokine release syndrome, insertional oncogenesis, and so on, have been associated with CAR-T cells.We are currently conducting clinical trials investigating the use of CRISPR gene therapy.Brazil has ample intellectual and technological capacity to participate in these historical advances and advance CRISPR in cancer therapy.In this work, we will present the ongoing efforts in Brazil regarding the application of CRISPR technology in engineering CAR-T cells and its clinical efficacy and safety in cancer treatment.